Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent

European Journal of Cancer

Volumn 45, Issue 8, 2009, Pages 1474-1484

  Lorusso, Girieca ^a,b   Vannini, Nicola ^a,c   Sogno, Ilaria ^a   Generoso, Luca ^a   Garbisa, Spiridione ^d   Noonan, Douglas M ^a,c   Albini, Adriana ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Chemoprevention; Endothelial cells; Hyperforin; Inflammation; Monocytes; Neutrophils

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; HYPERFORIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MATRIGEL; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSAY; CAPILLARY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CELL SURVIVAL; CHEMOTAXIS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; EMBRYO; ENDOTHELIUM CELL; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KAPOSI SARCOMA; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; STIMULUS; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BICYCLO COMPOUNDS; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHLOROGLUCINOL; TERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65249172014     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.014     Document Type: Article

References (56)

1. Barnes J., Anderson L.A., and Phillipson J.D. St. John's wort (Hypericum perforatum L): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 53 5 (2001) 583-600
2. Mueller B.M. St. John's Wort for depressive disorders: results of an outpatient study with the Hypericum preparation HYP 811. Adv Ther 15 2 (1998) 109-116
3. Singer A., Wonnemann M., and Muller W.E. Hyperforin, a major antidepressant constituent of St. John's Wort inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 290 3 (1999) 1363-1368
4. Bystrov N., Dobrynin V., Kolosov M., Chernov B., and Chervin I. Structure of the cromophoriic part of hyperforin. Dokl Akad Nauk SSSR 225 6 (1975) 1327-1328
5. Cervo L., Rozio M., Ekalle-Soppo C.B., Guiso G., Morazzoni P., and Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berl) 164 4 (2002) 423-428
6. Krusekopf S., and Roots I. St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharmacogenet Genomics 15 11 (2005) 817-829
7. Albert D., Zundorf I., Dingermann T., Muller W.E., Steinhilber D., and Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 64 12 (2002) 1767-1775
8. Schempp C.M., Winghofer B., Ludtke R., Simon-Haarhaus B., Schopf E., and Simon J.C. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol 142 5 (2000) 979-984
9. Beerhues L. Hyperforin. Phytochemistry 67 20 (2006) 2201-2207
10. 2+ mobilization and functional leukocyte responses by hyperforin. Biochem Pharmacol 67 8 (2004) 1531-1539
11. Quiney C., Billard C., Mirshahi P., Fourneron J.D., and Kolb J.P. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia 20 4 (2006) 583-589
12. Schempp C.M., Pelz K., Wittmer A., Schopf E., and Simon J.C. Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet 353 9170 (1999) 2129
13. Schempp C.M., Kirkin V., Simon-Haarhaus B., et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 21 8 (2002) 1242-1250
14. Gartner M., Muller T., Simon J.C., Giannis A., and Sleeman J.P. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. Chembiochem 6 1 (2005) 171-177
15. Dona M., Dell'Aica I., Pezzato E., et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 64 17 (2004) 6225-6232
16. Schempp C.M., Kiss J., Kirkin V., et al. Hyperforin acts as an angiogenesis inhibitor. Planta Med 71 11 (2005) 999-1004
17. Medina M.A., Martinez-Poveda B., Amores-Sanchez M.I., and Quesada A.R. Hyperforin: more than an antidepressant bioactive compound?. Life Sci 79 2 (2006) 105-111
18. Martinez-Poveda B., Quesada A.R., and Medina M.A. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Int J Cancer 117 5 (2005) 775-780
19. Dell'Aica I., Caniato R., Biggin S., and Garbisa S. Matrix proteases, green tea, and St. John's wort: biomedical research catches up with folk medicine. Clin Chim Acta 381 1 (2007) 69-77
20. Dell'Aica I., Niero R., Piazza F., et al. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J Pharmacol Exp Ther 321 2 (2007) 492-500
21. Chatterjee S, Erdelmeier C, Klessing K, Marmé D, Schächtele C. Stable Hyperforin salts: method for producing them and their use in the treatment of Alzheimer's disease. World patent PCT WO 99/41220 1999 (Aug 19).
22. Albini A., and Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7 2 (2007) 139-147
23. Albini A., Tosetti F., Benelli R., and Noonan D.M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65 23 (2005) 10637-10641
24. Albini A., and Benelli R. The chemoivasion assay: a method to asses tumor and endothelial cell invasion and its modulation. Nat Protoc 2 (2007) 504-511
25. Albini A., Paglieri I., Orengo G., et al. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. Aids 11 6 (1997) 713-721
26. Albini A., Iwamoto Y., Kleinman H.K., et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47 12 (1987) 3239-3245
27. Grant D.S., Tashiro K.-.I., Segui-Real B., Yamada Y., Martin G.R., and Kleinman H.K. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58 (1989) 933-943
28. Albini A., Fontanini G., Masiello L., et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. Aids 8 9 (1994) 1237-1244
29. Sciacca F.L., Sturzl M., Bussolino F., et al. Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. J Immunol 153 10 (1994) 4816-4825
30. Benelli R., Morini M., Carrozzino F., et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. Faseb J 16 2 (2002) 267-269 10.1096/fj.01-0651fje
31. Salcedo R., Ponce M.L., Young H.A., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 1 (2000) 34-40
32. Koch A.E., Polverini P.J., Kunkel S.L., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 5089 (1992) 1798-1801
33. Li A., Dubey S., Varney M.L., Dave B.J., and Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170 6 (2003) 3369-3376
34. Albini A., Noonan D.M., and Ferrari N. Molecular pathways for cancer angioprevention. Clin Cancer Res 13 15 Pt 1 (2007) 4320-4325
35. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
36. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 1 (2006) 24-37
37. Noonan D.M., De Lerma Barbaro A., Vannini N., Mortara L., and Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27 1 (2008) 31-40
38. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
39. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 10 (2002) 727-739
40. Sporn M.B., and Liby K.T. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2 10 (2005) 518-525
41. Gescher A., and Gerhauser C. Cancer chemopreventive agents in plants - a continuing challenge. Planta Med 74 13 (2008) 1523-1525
42. Verschoyle R.D., Steward W.P., and Gescher A.J. Putative cancer chemopreventive agents of dietary origin-how safe are they?. Nutr Cancer 59 2 (2007) 152-162
43. Biber A., Fischer H., Romer A., and Chatterjee S.S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31 Suppl 1 (1998) 36-43
44. Muller W.E. Current St John's wort research from mode of action to clinical efficacy. Pharmacol Res 47 2 (2003) 101-109
45. Benelli R., Lorusso G., Albini A., and Noonan D.M. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 12 24 (2006) 3101-3115
46. Scapini P., Morini M., Tecchio C., et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 172 8 (2004) 5034-5040
47. Barcelos L.S., Talvani A., Teixeira A.S., et al. Impaired inflammatory angiogenesis, but not leukocyte influx, in mice lacking TNFR1. J Leukoc Biol 78 2 (2005) 352-358
48. Garbisa S., Biggin S., Cavallarin N., Sartor L., Benelli R., and Albini A. Tumor invasion: molecular shears blunted by green tea. Nat Med 5 11 (1999) 1216
49. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 6 3 (2004) 203-208
50. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 31 (2001) 4188-4197
51. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 7092 (2006) 431-436
52. D'Incalci M., Brunelli D., Marangon E., et al. Modulation of gene transcription by natural products-a viable anticancer strategy. Curr Pharm Des 13 27 (2007) 2744-2750
53. Bork P.M., Bacher S., Schmitz M.L., Kaspers U., and Heinrich M. Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med 65 4 (1999) 297-300
54. Menegazzi M., Novelli M., Beffy P., et al. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line. Int J Biochem Cell Biol 40 8 (2008) 1509-1521
55. Tedeschi E., Menegazzi M., Margotto D., Suzuki H., Forstermann U., and Kleinert H. Anti-inflammatory actions of St. John's wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha (STAT-1alpha) activation. J Pharmacol Exp Ther 307 1 (2003) 254-261
56. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545